Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with the overproduction and accumulation of amyloid-β peptide and hyperphosphorylation of tau proteins in the brain. Despite extensive research on the amyloid-based mechanism of AD pathogenesis, the underlying cause of AD is not fully understood. No disease-modifying therapies currently exist, and numerous clinical trials have failed to demonstrate any benefits. The recent discovery that the amyloid-β peptide has antimicrobial activities supports the possibility of an infectious aetiology of AD and suggests that amyloid-β plaque formation might be induced by infection. AD patients have a weakened blood-brain barrier and immune system and are thus at elevated risk of microbial infections. Such infections can cause chronic neuroinflammation, production of the antimicrobial amyloid-β peptide, and neurodegeneration. Various pathogens, including viruses, bacteria, fungi, and parasites have been associated with AD. Most research in this area has focused on individual pathogens, with herpesviruses and periodontal bacteria being most frequently implicated. The purpose of this review is to highlight the potential role of multi-pathogen infections in AD. Recognition of the potential coexistence of multiple pathogens and biofilms in AD's aetiology may stimulate the development of novel approaches to its diagnosis and treatment. Multiple diagnostic tests could be applied simultaneously to detect major pathogens, followed by anti-microbial treatment using antiviral, antibacterial, antifungal, and anti-biofilm agents.

Department of Experimental Biology and RECETOX Faculty of Science Loschmidt Laboratories Masaryk University Kamenice 5 625 00 Brno Czech Republic

International Clinical Research Center St Anne's University Hospital Brno Pekarska 53 656 91 Brno Czech Republic

Zobrazit více v PubMed

Guerreiro R, Bras J. The age factor in Alzheimer’s disease. Genome Med [Internet]. 2015 [cited 2021 Jan 3];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617238/. PubMed PMC

Tilley L, Morgan K, Kalsheker N. Genetic risk factors in Alzheimer’s disease. Mol Pathol. 1998;51:293–304. doi: 10.1136/mp.51.6.293. PubMed DOI PMC

Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer’s disease. Curr Atheroscler Rep. 2004;6:261–266. doi: 10.1007/s11883-004-0056-z. PubMed DOI

Julien J, Joubert S, Ferland M-C, Frenette LC, Boudreau-Duhaime MM, Malo-Véronneau L, et al. Association of traumatic brain injury and Alzheimer disease onset: a systematic review. Ann Phys Rehabil Med. 2017;60:347–356. doi: 10.1016/j.rehab.2017.03.009. PubMed DOI

Killin LOJ, Starr JM, Shiue IJ, Russ TC. Environmental risk factors for dementia: a systematic review. BMC Geriatr [Internet]. 2016 [cited 2021 Jan 3];16. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059894/. PubMed PMC

Gosztyla ML, Brothers HM, Robinson SR. Alzheimer’s amyloid-β is an antimicrobial peptide: a review of the evidence. J Alzheimers Dis. 2018;62:1495–1506. doi: 10.3233/JAD-171133. PubMed DOI

Atwood CS, Bowen RL, Smith MA, Perry G. Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res Brain Res Rev. 2003;43:164–178. doi: 10.1016/S0165-0173(03)00206-6. PubMed DOI

Pajoohesh-Ganji A, Burns MP, Pal-Ghosh S, Tadvalkar G, Hokenbury NG, Stepp MA, et al. Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury. Brain Res. 2014;1560:73–82. doi: 10.1016/j.brainres.2014.02.049. PubMed DOI PMC

Brothers HM, Gosztyla ML, Robinson SR. The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci. 2018;10:118. doi: 10.3389/fnagi.2018.00118. PubMed DOI PMC

Puzzo D, Arancio O. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J Alzheimer’s Dis. 2013;33:S111–S120. doi: 10.3233/JAD-2012-129033. PubMed DOI PMC

Morley JE, Farr SA. The role of amyloid-beta in the regulation of memory. Biochem Pharmacol. 2014;88:479–485. doi: 10.1016/j.bcp.2013.12.018. PubMed DOI

Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clin Anat. 1995;8:429–431. doi: 10.1002/ca.980080612. PubMed DOI

Sochocka M, Zwolińska K, Leszek J. The infectious etiology of Alzheimer’s disease. Curr Neuropharmacol. 2017;15:996–1009. doi: 10.2174/1570159X15666170313122937. PubMed DOI PMC

Alonso R, Pisa D, Fernández-Fernández AM, Carrasco L. Infection of fungi and bacteria in brain tissue from elderly persons and patients with Alzheimer’s disease. Front Aging Neurosci [Internet]. 2018 [cited 2018 Jun 16];10. Available from: https://www.frontiersin.org/article/10.3389/fnagi.2018.00159/full. PubMed DOI PMC

Bu X-L, Yao X-Q, Jiao S-S, Zeng F, Liu Y-H, Xiang Y, et al. A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol. 2015;22:1519–1525. doi: 10.1111/ene.12477. PubMed DOI

Carrasco L, Pisa D, Alonso R. Polymicrobial infections and neurodegenerative diseases. Curr Clin Micro Rpt. 2020;7:20–30. doi: 10.1007/s40588-020-00139-3. DOI

Carter CJ. Genetic, transcriptome, proteomic, and epidemiological evidence for blood–brain barrier disruption and polymicrobial brain invasion as determinant factors in Alzheimer’s disease. J Alzheimers Dis Rep. 2017;1:125–157. doi: 10.3233/ADR-170017. PubMed DOI PMC

Miklossy J. Chronic inflammation and amyloidogenesis in Alzheimer’s disease—role of Spirochetes. J Alzheimers Dis. 2008;13:381–391. doi: 10.3233/JAD-2008-13404. PubMed DOI

Pisa D, Alonso R, Marina AI, Rábano A, Carrasco L. Human and microbial proteins from corpora amylacea of Alzheimer’s disease. Sci Rep. 2018;8:9880. doi: 10.1038/s41598-018-28231-1. PubMed DOI PMC

Pisa D, Alonso R, Fernández-Fernández AM, Rábano A, Carrasco L. Polymicrobial infections in brain tissue from Alzheimer’s disease patients. Sci Rep. 2017;7:5559. doi: 10.1038/s41598-017-05903-y. PubMed DOI PMC

Elkind MSV. Infectious burden: a new risk factor and treatment target for atherosclerosis. Infect Disord Drug Targets. 2010;10:84–90. doi: 10.2174/187152610790963519. PubMed DOI PMC

Soares BP, Provenzale JM. Imaging of Herpesvirus infections of the CNS. Am J Roentgenol. 2015;206:39–48. doi: 10.2214/AJR.15.15314. PubMed DOI

Lövheim H, Olsson J, Weidung B, Johansson A, Eriksson S, Hallmans G, et al. Interaction between cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer’s disease development. J Alzheimers Dis. 2018;61:939–945. doi: 10.3233/JAD-161305. PubMed DOI

Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Reactivation of herpes simplex virus type 1 is associated with cytomegalovirus and age. J Med Virol. 2012;84:1797–1802. doi: 10.1002/jmv.23397. PubMed DOI PMC

Tarter KD, Simanek AM, Dowd JB, Aiello AE. Persistent viral pathogens and cognitive impairment across the life course in the third national health and nutrition examination survey. J Infect Dis. 2014;209:837–844. doi: 10.1093/infdis/jit616. PubMed DOI PMC

Watson AMM, Prasad KM, Klei L, Wood JA, Yolken RH, Gur RC, et al. Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol Med. 2013;43:1023–1031. doi: 10.1017/S003329171200195X. PubMed DOI

Rodriguez JD, Royall D, Daum LT, Kagan-Hallet K, Chambers JP. Amplification of herpes simplex type 1 and human herpes type 5 viral DNA from formalin-fixed Alzheimer brain tissue. Neurosci Lett. 2005;390:37–41. doi: 10.1016/j.neulet.2005.07.052. PubMed DOI

Lin W-R, Wozniak MA, Cooper RJ, Wilcock GK, Itzhaki RF. Herpesviruses in brain and Alzheimer’s disease. J Pathol. 2002;197:395–402. doi: 10.1002/path.1127. PubMed DOI

Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, et al. Herpes virus in Alzheimer’s disease: relation to progression of the disease. Neurobiol Aging. 2014;35:122–129. doi: 10.1016/j.neurobiolaging.2013.06.024. PubMed DOI

Readhead B, Haure-Mirande J-V, Funk CC, Richards MA, Shannon P, Haroutunian V, et al. Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 2018;99(64–82):e7. PubMed PMC

Hemling N, Röyttä M, Rinne J, Pöllänen P, Broberg E, Tapio V, et al. Herpesviruses in brains in Alzheimer’s and Parkinson’s diseases. Ann Neurol. 2003;54:267–271. doi: 10.1002/ana.10662. PubMed DOI

Kittur SD, Hoh JH, Kawas CH, Hayward GS, Endo H, Adler WH. A molecular hybridization study for the presence of Herpes simplex, cytomegalovirus and Epstein-Barr virus in brain and blood of Alzheimer’s disease patients. Arch Gerontol Geriatr. 1992;15:35–41. doi: 10.1016/0167-4943(92)90038-6. PubMed DOI

Lin WR, Casas I, Wilcock GK, Itzhaki RF. Neurotropic viruses and Alzheimer’s disease: a search for varicella zoster virus DNA by the polymerase chain reaction. J Neurol Neurosurg Psychiatry. 1997;62:586–589. doi: 10.1136/jnnp.62.6.586. PubMed DOI PMC

Lurain NS, Hanson BA, Martinson J, Leurgans SE, Landay AL, Bennett DA, et al. Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis. 2013;208:564–572. doi: 10.1093/infdis/jit210. PubMed DOI PMC

Taylor GR, Crow TJ. Viruses in human brains: a search for cytomegalovirus and herpes virus 1 DNA in necropsy tissue from normal and neuropsychiatric cases. Psychol Med. 1986;16:289–295. doi: 10.1017/S0033291700009107. PubMed DOI

Westman G, Blomberg J, Yun Z, Lannfelt L, Ingelsson M, Eriksson B-M. Decreased HHV-6 IgG in Alzheimer’s disease. Front Neurol [Internet]. 2017 [cited 2018 Mar 28];8. Available from: http://journal.frontiersin.org/article/10.3389/fneur.2017.00040/full. PubMed DOI PMC

Noguchi H, Moore JW. A demonstration of treponema pallidum in the brain in cases of general paralysis. J Exp Med. 1913;17:232–238. doi: 10.1084/jem.17.2.232. PubMed DOI PMC

MacDonald AB, Miranda JM. Concurrent neocortical borreliosis and Alzheimer’s disease. Hum Pathol. 1987;18:759–761. doi: 10.1016/S0046-8177(87)80252-6. PubMed DOI

Miklossy J. Alzheimer’s disease—a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria. J Neuroinflammation. 2011;8:90. doi: 10.1186/1742-2094-8-90. PubMed DOI PMC

Miklossy J. Historic evidence to support a causal relationship between spirochetal infections and Alzheimer’s disease. Front Aging Neurosci. 2015;7:46. doi: 10.3389/fnagi.2015.00046. PubMed DOI PMC

Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer’s disease. Oral Microbiol Immunol. 2002;17:113–118. doi: 10.1046/j.0902-0055.2001.00100.x. PubMed DOI

Kamer AR, Craig RG, Pirraglia E, Dasanayake AP, Norman RG, Boylan RJ, et al. TNF-α and antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects. J Neuroimmunol. 2009;216:92–97. doi: 10.1016/j.jneuroim.2009.08.013. PubMed DOI PMC

Beydoun MA, Beydoun HA, Weiss J, Hossain S, El-Hajj ZW, Zonderman AB. Helicobacter pylori, periodontal pathogens, and their interactive association with incident all-cause and Alzheimer’s disease dementia in a large national survey. Mol Psychiatry. Nature Publishing Group; 2020;1–16. PubMed

Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, et al. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimer’s Dementia. 2012;8:196–203. doi: 10.1016/j.jalz.2011.04.006. PubMed DOI PMC

Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL, et al. 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer’s post-mortem brain. Front Aging Neurosci. 2017;9:195. doi: 10.3389/fnagi.2017.00195. PubMed DOI PMC

Siddiqui H, Eribe E, Singhrao S, Olsen I. High throughput sequencing detects gingivitis and periodontal oral bacteria in Alzheimer’s disease autopsy brains. Neurol Res. 2019;1:3.

Alonso R, Pisa D, Rábano A, Carrasco L. Alzheimer’s disease and disseminated mycoses. Eur J Clin Microbiol Infect Dis. 2014;33:1125–1132. doi: 10.1007/s10096-013-2045-z. PubMed DOI

Alonso R, Pisa D, Marina AI, Morato E, Rábano A, Carrasco L. Fungal infection in patients with Alzheimer’s disease. J Alzheimers Dis. 2014;41:301–311. doi: 10.3233/JAD-132681. PubMed DOI

Alonso R, Pisa D, Rábano A, Rodal I, Carrasco L. Cerebrospinal fluid from Alzheimer’s disease patients contains fungal proteins and DNA. J Alzheimers Dis. 2015;47:873–876. doi: 10.3233/JAD-150382. PubMed DOI

Pisa D, Alonso R, Rábano A, Rodal I, Carrasco L. Different brain regions are infected with fungi in Alzheimer’s disease. scientific reports [Internet]. 2015 [cited 2018 Mar 28];5. Available from: http://www.nature.com/articles/srep15015. PubMed PMC

Alonso R, Pisa D, Aguado B, Carrasco L. Identification of fungal species in brain tissue from Alzheimer’s disease by next-generation sequencing. J Alzheimers Dis. 2017;58:55–67. doi: 10.3233/JAD-170058. PubMed DOI

Strandberg TE, Pitkala KH, Linnavuori KH, Tilvis RS. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke. 2003;34:2126–2131. doi: 10.1161/01.STR.0000086754.32238.DA. PubMed DOI

Strandberg TE, Pitkala K, Eerola J, Tilvis R, Tienari PJ. Interaction of herpesviridae, APOE gene, and education in cognitive impairment. Neurobiol Aging. 2005;26:1001–1004. doi: 10.1016/j.neurobiolaging.2004.09.008. PubMed DOI

Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, Elkind MSV. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology. 2013;80:1209–1215. doi: 10.1212/WNL.0b013e3182896e79. PubMed DOI PMC

Wright CB, Gardener H, Dong C, Yoshita M, DeCarli C, Sacco RL, et al. Infectious burden and cognitive decline in the Northern Manhattan Study. J Am Geriatr Soc. 2015;63:1540–1545. doi: 10.1111/jgs.13557. PubMed DOI PMC

Renvoize EB, Awad IO, Hambling MH. A sero-epidemiological study of conventional infectious agents in Alzheimer’s disease. Age Ageing. 1987;16:311–314. doi: 10.1093/ageing/16.5.311. PubMed DOI

Flegr J, Prandota J, Sovičková M, Israili ZH. Toxoplasmosis—a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE. 2014;9:e90203. doi: 10.1371/journal.pone.0090203. PubMed DOI PMC

Fabiani S, Pinto B, Bruschi F. Toxoplasmosis and neuropsychiatric diseases: can serological studies establish a clear relationship? Neurol Sci. 2013;34:417–425. doi: 10.1007/s10072-012-1197-4. PubMed DOI

Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neuro Immuno Modul. 2009;16:122–133. PubMed

Mahmoudvand H, Sheibani V, Shojaee S, Mirbadie SR, Keshavarz H, Esmaeelpour K, et al. Toxoplasma gondii infection potentiates cognitive impairments of Alzheimer’s disease in the BALB/c mice. J Parasitol. 2016;102:629–635. doi: 10.1645/16-28. PubMed DOI

Torres L, Robinson S-A, Kim D-G, Yan A, Cleland TA, Bynoe MS. Toxoplasma gondii alters NMDAR signaling and induces signs of Alzheimer’s disease in wild-type, C57BL/6 mice. J Neuroinflammation. 2018;15:57. doi: 10.1186/s12974-018-1086-8. PubMed DOI PMC

Kusbeci OY, Miman O, Yaman M, Aktepe OC, Yazar S. Could Toxoplasma gondii have any role in Alzheimer disease? Alzheimer Dis Assoc Disord. 2011;25:1–3. doi: 10.1097/WAD.0b013e3181f73bc2. PubMed DOI

Deshayes S, Bonhomme J, de La Blanchardière A. Neurotoxocariasis: a systematic literature review. Infection. 2016;44:565–574. doi: 10.1007/s15010-016-0889-8. PubMed DOI

Finsterer J, Auer H. Neurotoxocarosis. Rev Inst Med Trop Sao Paulo. 2007;49:279–287. doi: 10.1590/S0036-46652007000500002. PubMed DOI

Wiwanitkit V. Dementia and neurocysticercosis. Acta Neurol Taiwan. 2014;23:1–3. PubMed

Gale SD, Erickson LD, Berrett A, Brown BL, Hedges DW. Infectious disease burden and cognitive function in young to middle-aged adults. Brain Behav Immun. 2016;52:161–168. doi: 10.1016/j.bbi.2015.10.014. PubMed DOI

Nimgaonkar VL, Yolken RH, Wang T, Chang C-CH, McClain L, McDade E, et al. Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort. Alzheimer Dis Assoc Disord. 2016;30:216–222. doi: 10.1097/WAD.0000000000000133. PubMed DOI PMC

Kuboshima S, Tsuruoka K, Shirai S, Sasaki H, Sakurada T, Miura H, et al. An autopsy case of microscopic polyangiitis complicated with pulmonary aspergilloma and cytomegalovirus pneumonia. Nihon Jinzo Gakkai Shi. 2007;49:125–129. PubMed

Gale SD, Erickson LD, Brown BL, Hedges DW. Interaction between Helicobacter pylori and latent toxoplasmosis and demographic variables on cognitive function in young to middle-aged adults. PLoS One. [Internet]. 2015 [cited 2019 Mar 13];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295891/. PubMed PMC

Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Transl Neurodegener [Internet]. 2018 [cited 2019 Mar 20];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789526/. PubMed PMC

Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, et al. β-Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1. Biogerontology. 2015;16:85–98. doi: 10.1007/s10522-014-9538-8. PubMed DOI

Eimer WA, Vijaya Kumar DK, Shanmugam NKN, Rodriguez AS, Mitchell T, Washicosky KJ, et al. Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron. 2018;99(56–63):e3. PubMed PMC

Kumar DKV, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med. 2016;8:340ra72–340ra72. doi: 10.1126/scitranslmed.aaf1059. PubMed DOI PMC

Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS ONE. 2010;5:e9505. doi: 10.1371/journal.pone.0009505. PubMed DOI PMC

Fulop T, Witkowski JM, Bourgade K, Khalil A, Zerif E, Larbi A, et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer’s disease? Front Aging Neurosci [Internet]. 2018 [cited 2019 Feb 10];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066504/. PubMed PMC

Lim SL, Rodriguez-Ortiz CJ, Kitazawa M. Infection, systemic inflammation, and Alzheimer’s disease. Microbes Infect. 2015;17:549–556. doi: 10.1016/j.micinf.2015.04.004. PubMed DOI

Tzeng N-S, Chung C-H, Lin F-H, Chiang C-P, Yeh C-B, Huang S-Y, et al. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—a nationwide, population-based cohort study in Taiwan. Neurotherapeutics. 2018;15:417–429. doi: 10.1007/s13311-018-0611-x. PubMed DOI PMC

Chen VC-H, Wu S-I, Huang K-Y, Yang Y-H, Kuo T-Y, Liang H-Y, et al. Herpes zoster and dementia: a nationwide population-based cohort study. J Clin Psychiatry. 2017 PubMed

Montoya JG, Neely MN, Gupta S, Lunn MR, Loomis KS, Pritchett JC, et al. Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction. J Clin Virol. 2012;55:40–45. doi: 10.1016/j.jcv.2012.05.016. PubMed DOI

Devanand DP. Viral hypothesis and antiviral treatment in Alzheimer’s disease. Curr Neurol Neurosci Rep. 2018;18:55. doi: 10.1007/s11910-018-0863-1. PubMed DOI PMC

Devanand DP, Andrews H, Kreisl WC, Razlighi Q, Gershon A, Stern Y, et al. Antiviral therapy: valacyclovir treatment of Alzheimer’s disease (VALAD) trial: protocol for a randomised, double-blind, placebo-controlled, treatment trial. BMJ Open Br Med J Publ Group. 2020;10:e032112. PubMed PMC

Namba Y, Kawatsu K, Izumi S, Ueki A, Ikeda K. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet. 1992;340:978. doi: 10.1016/0140-6736(92)92870-L. PubMed DOI

Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease: antibiotics for Alzheimer disease. J Am Geriatr Soc. 2004;52:381–387. doi: 10.1111/j.1532-5415.2004.52109.x. PubMed DOI

Costa R, Speretta E, Crowther DC, Cardoso I. Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease. J Biol Chem. 2011;286:41647–41655. doi: 10.1074/jbc.M111.274548. PubMed DOI PMC

Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001;487:404–407. doi: 10.1016/S0014-5793(00)02380-2. PubMed DOI

Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, et al. Inhibition of amyloid protein aggregation and neurotoxicity by rifampicin its possible function as a hydroxyl radical scavenger. J Biol Chem. 1996;271:6839–6844. doi: 10.1074/jbc.271.12.6839. PubMed DOI

Umeda T, Ono K, Sakai A, Yamashita M, Mizuguchi M, Klein WL, et al. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers. Brain. 2016;139:1568–1586. doi: 10.1093/brain/aww042. PubMed DOI

Balducci C, Forloni G. Doxycycline for Alzheimer’s disease: fighting β-amyloid oligomers and neuroinflammation. Front Pharmacol [Internet]. 2019 [cited 2020 Jun 29];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616274/. PubMed PMC

Kountouras J, Boziki M, Gavalas E, Zavos C, Grigoriadis N, Deretzi G, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer’s disease. J Neurol. 2009;256:758–767. doi: 10.1007/s00415-009-5011-z. PubMed DOI

Budni J, Garcez ML, de Medeiros J, Cassaro E, Bellettini-Santos T, Mina F, et al. The anti-inflammatory role of minocycline in Alzheimer’s disease. Curr Alzheimer Res. 2016;13:1319–1329. doi: 10.2174/1567205013666160819124206. PubMed DOI

El-Shimy IA, Heikal OA, Hamdi N. Minocycline attenuates Aβ oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Aβ fibrils phagocytosis. Neurosci Lett. 2015;609:36–41. doi: 10.1016/j.neulet.2015.10.024. PubMed DOI

Fu W-Y, Wang X, Ip NY. Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s disease: mechanisms, drug candidates, and new opportunities. ACS Chem Neurosci. 2019;10:872–879. doi: 10.1021/acschemneuro.8b00402. PubMed DOI

Garcez ML, Mina F, Bellettini-Santos T, Carneiro FG, Luz AP, Schiavo GL, et al. Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid β (1–42) in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2017;77:23–31. doi: 10.1016/j.pnpbp.2017.03.010. PubMed DOI

Howard R, Zubko O, Gray R, Bradley R, Harper E, Kelly L, et al. Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT [Internet]. Southampton (UK): NIHR Journals Library; 2020 [cited 2020 Jun 29]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK556206/. PubMed

Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv Am Assoc Adv Sci. 2019;5:eaau3333. PubMed PMC

Arastu-Kapur S, Nguyen M, Raha D, Ermini F, Haditsch U, Araujo J, et al. Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388. Pharmacol Res Perspect. 2020;8:e00562. doi: 10.1002/prp2.562. PubMed DOI PMC

Góralska K, Blaszkowska J, Dzikowiec M. Neuroinfections caused by fungi. Infection. 2018;46:443–459. doi: 10.1007/s15010-018-1152-2. PubMed DOI PMC

Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31:e00057–e117. doi: 10.1128/CMR.00057-17. PubMed DOI PMC

Vidal JE, Sztajnbok J, Seguro AC. Eosinophilic meningoencephalitis due to Toxocara canis: case report and review of the literature. Am J Trop Med Hyg. 2003;69:341–343. doi: 10.4269/ajtmh.2003.69.341. PubMed DOI

Ma G, Holland CV, Wang T, Hofmann A, Fan C-K, Maizels RM, et al. Human toxocariasis. Lancet Infect Dis. 2018;18:e14–24. doi: 10.1016/S1473-3099(17)30331-6. PubMed DOI

Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Escalante D, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14:687–695. doi: 10.1016/S1473-3099(14)70779-0. PubMed DOI PMC

Costerton JW, Geesey GG, Cheng KJ. How bacteria stick. Sci Am. 1978;238:86–95. doi: 10.1038/scientificamerican0178-86. PubMed DOI

Roilides E, Simitsopoulou M, Katragkou A, Walsh TJ. How biofilms evade host defenses. Microbiol Spectr. 2015;3. PubMed

Pais-Correia A-M, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A, et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med. 2010;16:83–89. doi: 10.1038/nm.2065. PubMed DOI

Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog Dis [Internet]. 2016 [cited 2019 Mar 23];74. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975230/. PubMed PMC

Mazaheritehrani E, Sala A, Orsi CF, Neglia RG, Morace G, Blasi E, et al. Human pathogenic viruses are retained in and released by Candida albicans biofilm in vitro. Virus Res. 2014;179:153–160. doi: 10.1016/j.virusres.2013.10.018. PubMed DOI

Ascione C, Sala A, Mazaheri-Tehrani E, Paulone S, Palmieri B, Blasi E, et al. Herpes simplex virus-1 entrapped in Candida albicans biofilm displays decreased sensitivity to antivirals and UVA1 laser treatment. Ann Clin Microbiol Antimicrob. 2017;16:72. doi: 10.1186/s12941-017-0246-5. PubMed DOI PMC

Shirtliff ME, Peters BM, Jabra-Rizk MA. Cross-kingdom interactions: Candida albicans and bacteria. FEMS Microbiol Lett. 2009;299:1–8. doi: 10.1111/j.1574-6968.2009.01668.x. PubMed DOI PMC

Allen HB. Alzheimer’s disease: assessing the role of spirochetes, biofilms, the immune system, and amyloid-β with regard to potential treatment and prevention. J Alzheimers Dis. 2016;53:1271–1276. doi: 10.3233/JAD-160388. PubMed DOI PMC

Miklossy J. Bacterial amyloid and DNA are important constituents of senile plaques: further evidence of the spirochetal and biofilm nature of senile plaques. J Alzheimers Dis. 2016;53:1459–1473. doi: 10.3233/JAD-160451. PubMed DOI PMC

Borghi E, Morace G, Borgo F, Rajendran R, Sherry L, Nile C, et al. New strategic insights into managing fungal biofilms. Front Microbiol [Internet]. 2015 [cited 2019 Mar 24];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594024/. PubMed PMC

Kamaruzzaman NF, Tan LP, Mat Yazid KA, Saeed SI, Hamdan RH, Choong SS, et al. Targeting the bacterial protective armour; challenges and novel strategies in the treatment of microbial biofilm. Materials (Basel). 2018;11. PubMed PMC

Montazeri M, Mehrzadi S, Sharif M, Sarvi S, Shahdin S, Daryani A. Activities of anti-toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review. Parasitol Res. 2018;117:3045–3057. doi: 10.1007/s00436-018-6027-z. PubMed DOI

Tardiolo G, Bramanti P, Mazzon E. Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Molecules [Internet]. 2018 [cited 2019 Mar 24];23. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320789/. PubMed PMC

Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2014;18:2942–2948. PubMed

Mahmoud Abd El-Baky R, El-Baky RMA, Ela DMMAE, Gad GFM. N-acetylcysteine inhibits and Eradicates<i> Candida albicans </i>Biofilms. Am J Infect Dis Microbiol. 2:122–30.

Feng J, Shi W, Miklossy J, Tauxe GM, McMeniman CJ, Zhang Y. Identification of essential oils with strong activity against stationary phase Borrelia burgdorferi. Antibiotics (Basel). 2018;7. PubMed PMC

Feng J, Zhang S, Shi W, Zubcevik N, Miklossy J, Zhang Y. Selective essential oils from spice or culinary herbs have high activity against stationary phase and biofilm Borrelia burgdorferi. Front Med (Lausanne) 2017;4:169. doi: 10.3389/fmed.2017.00169. PubMed DOI PMC

Nazzaro F, Fratianni F, Coppola R, Feo VD. Essential oils and antifungal activity. Pharmaceuticals (Basel). 2017;10. PubMed PMC

Fülöp T, Munawara U, Larbi A, Desroches M, Rodrigues S, Catanzaro M, et al. Targeting infectious agents as a therapeutic strategy in Alzheimer’s disease. CNS Drugs. 10.1007/s40263-020-00737-1. PubMed PMC

Panza F, Lozupone M, Solfrizzi V, Watling M, Imbimbo BP. Time to test antibacterial therapy in Alzheimer’s disease. Brain Oxford Acad. 2019;142:2905–2929. PubMed

Beason-Held LL, Goh JO, An Y, Kraut MA, O’Brien RJ, Ferrucci L, et al. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci. 2013;33:18008–18014. doi: 10.1523/JNEUROSCI.1402-13.2013. PubMed DOI PMC

Proal AD, Lindseth IA, Marshall TG. Microbe–microbe and host–microbe interactions drive microbiome dysbiosis and inflammatory processes. Discov Med. 2017;23:51–60. PubMed

Sochocka M, Donskow-Łysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer’s disease—a critical review. Mol Neurobiol. 2019;56:1841–1851. doi: 10.1007/s12035-018-1188-4. PubMed DOI PMC

Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflam. 2019;16:108. doi: 10.1186/s12974-019-1494-4. PubMed DOI PMC

Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017;7:13537. doi: 10.1038/s41598-017-13601-y. PubMed DOI PMC

Wheeler ML, Limon JJ, Bar AS, Leal CA, Gargus M, Tang J, et al. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe. 2016;19:865–873. doi: 10.1016/j.chom.2016.05.003. PubMed DOI PMC

Wypych TP, Marsland BJ. Antibiotics as instigators of microbial dysbiosis: implications for asthma and allergy. Trends Immunol. 2018;39:697–711. doi: 10.1016/j.it.2018.02.008. PubMed DOI

Liu S, Gao J, Zhu M, Liu K, Zhang H-L. Gut microbiota and dysbiosis in Alzheimer’s disease: implications for pathogenesis and treatment. Mol Neurobiol. 2020;57:5026–5043. doi: 10.1007/s12035-020-02073-3. PubMed DOI PMC

ServickNov. 9 K, 2018, Pm 2:45. Do gut bacteria make a second home in our brains? [Internet]. Science | AAAS. 2018 [cited 2019 Apr 21]. Available from: https://www.sciencemag.org/news/2018/11/do-gut-bacteria-make-second-home-our-brains.